disabling stroke Archives - NeuroNews International

Novel dual-functional therapy leads to clinical improvements in patients with disabling...

9 February 2026

Lumosa Therapeutics has announced positive results from two independent Phase 2 clinical trials of its novel stroke drug LT3001 (odatroltide). LT3001 is described by...

Write to us
Editor: Jamie Bell [email protected]
Advertising: Abbie Richardson [email protected]

United Kingdom:

BIBA Medical, Europe
526 Fulham Road, Fulham, London, SW6 5NR
TEL: +44 (0)20 7736 8788
Email: [email protected]

United States:

BIBA Medical, North America
155 North Wacker Drive, Suite 4250, Chicago, IL 60606
TEL: +1 949 723 9309
Email: [email protected]

Terms and Conditions | Privacy Policy

Tag: disabling stroke

Novel dual-functional therapy leads to clinical improvements in patients with disabling...